Personalized medicine is very much about fitting target profiles of drugs
towards disease mechanism(s). This report is a new and unique way of
stratifying and analyzing the global prostate cancer pipeline towards
personalized medicine and presents actionable analysis which allows you to
discover:
Where the competition is; Which targets, compound types and companies are
setting the path?
How much R&D effort has gone towards different targets and what is known
about the target?
Which pathways are targeted, by what and how?
What is truly new and unique in the prostate cancer pipeline?
How new and unique your target strategy really is
What overlapping competition you have from other companies and compound
types towards your therapeutic targets
Locate the right drugs to benchmark against and see were others may have
succeeded or failed before you.
BioSeeker builds its analysis on a comprehensive base of 394 prostate cancer
drugs from within the portfolio of 222 companies world-wide, from Ceased to
Marketed. We have identified 227 drug targets, which we have organized into
216 drug target strategies, and assessed them by four levels:
1. Individual Target: Shows you how individual targets tie into different
target strategies and their subsequent R&D progress.
2. Developmental Stage: Shows you the progress and maturation of different
target strategies. Identifies which target strategies are new and unique from
one developmental stage to the next.
3. Compound Type: Shows you the competitive landscape of target strategies
from a compound perspective, including crossover analysis of target strategies
among different compound types.
4. Company: Provides a cross-examination of each company's entire pipeline
on the basis of its defined drug target strategies, including a Competitive
Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.
Our Analysis includes:
Head-to-head target competing analysis
Significant drug target overlap analysis
Cross-sectional R&D profiling of individual drug targets.
Cross-over analysis of target strategies among different compound types.
Competitive Fall-Out analysis of the entire company pipeline: Answering
three core questions about each company's pipeline:
Where are we?
Where is our general and specific competition?
What is the level of competition where we want to be?
15 parameter deep corporate pipeline ranking, including both internal
and external pipeline factors.
The report serves as an external commercial advocate for your company's
interest in the prostate cancer pipeline by:
Better identifying benchmarking peers
Providing rationale for in/out licensing decisions of drug candidates
Performing proper drug due diligence
Strategies for commercial planning
Guiding Research & Development efforts
Table of Contents
Table of Contents
1. Executive Summary
2. About Cancer Highlights™
2.1. Cancer Focus Areas
2.2. Subscribe Today and Start Saving
2.2.1. Type of License
2.3. Additional Information
2.4. BioSeeker Group's Oncology Team
3. Methodology
3.1. Cancer Highlights'™ Five Pillar Drug Assessment
4. Table of Contents
4.1. List of Figures
4.2. List of Tables
5. Introduction
5.1. The Scope of this Report
5.2. Definitions
5.3. Abbreviations
6. Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment
6.1. Drug Repositioning in Oncology
6.2. Introduction to Targets of Prostate Cancer Drugs
6.2.1. Acid Phosphatase Activity Targets
6.2.2. Auxiliary Transport Protein Activity Targets
6.2.3. Calcium Ion Binding Targets
6.2.4. Carboxy-lyase Activity Targets
6.2.5. Carboxypeptidase Activity Targets
6.2.6. Catalytic Activity Targets
6.2.7. Cell Adhesion Molecule Activity Targets
6.2.8. Chaperone Activity Targets
6.2.9. Chemokine Activity Targets
6.2.10. Complement Activity Targets
6.2.11. Cysteine-type Peptidase Activity Targets
6.2.12. Cytokine Activity Targets
6.2.13. DNA Binding Targets
6.2.14. DNA Repair Protein Targets
6.2.15. DNA Topoisomerase Activity Targets
6.2.16. DNA-directed DNA Polymerase Activity Targets
6.2.17. Extracellular Ligand-gated Ion Channel Activity Targets
6.2.62. Voltage-gated Ion Channel Activity Targets
6.2.63. Other Targets
6.3. Mutation Profiles of Prostate Cancer Drug Targets
6.3.1. Targets of Prostate Cancer Drugs Present in the Cancer Gene
Census and in the Catalogue of Somatic Mutations in Cancer
6.4. Prostate Cancer Therapeutics is Stimulated by Available Structure
Data on Targets
6.5. Target-Target Interactions among Identified Targets of Prostate
Cancer Drugs
6.6. The Drug-Target Competitive Landscape
6.7. Protein Expression Levels of Identified Targets of Prostate Cancer
Drugs
6.8. Pathway Assessment of Prostate Cancer Drugs
6.8.1. Tools for Analysis of Cancer Pathways
6.8.2. Pathway Assessment
7. Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development
7.1. Pre-registrered and Marketed: New and Unique Drug Target Strategies
of Prostate Cancer Drugs
7.2. Phase III Clinical Development: New and Unique Drug Target Strategies
of Prostate Cancer Drugs
7.3. Phase II Clinical Development: New and Unique Drug Target Strategies
of Prostate Cancer Drugs
7.4. Phase I Clinical Development: New and Unique Drug Target Strategies
of Prostate Cancer Drugs
7.5. Preclinical Development: New and Unique Drug Target Strategies of
Prostate Cancer Drugs
7.6. Drug Target Strategies of Suspended or Terminated Prostate Cancer
Drugs
7.7. Target Strategy Development Profiles of Prostate Cancer Drugs
7.7.1. Marketed
7.7.2. Pre-registration
7.7.3. Phase III
7.7.4. Phase II
7.7.5. Phase I
7.7.6. Preclinical
7.7.7. No Data
7.7.8. Suspended
7.7.9. Ceased
7.8. The Competition Through Close Mechanistic Approximation of Prostate
Cancer Drugs
8. Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy
8.1. Small Molecules
8.1.1. Background
8.1.2. Target Strategies of Small Molecule Drugs
8.2. Peptide & Protein Drugs
8.2.1. Background
8.2.2. Target Strategies of Peptide and Protein Drugs
8.3. Antibodies
8.3.1. Background
8.3.2. Target Strategies of Antibody Drugs
8.4. Nucleic Acid Therapies
8.4.1. Background
8.4.2. Target Strategies of Nucleic Acid Drugs
8.5. Cell & Gene Therapy
8.5.1. Background
8.5.2. Target Strategies of Cell and Gene Therapy Drugs
8.6. Drug Delivery and Nanotechnology
8.6.1. Background
8.6.2. Target Strategies of Reformulated Drugs
8.7. Compound Strategies based on Sub-Cellular Localization of Drug Targets
9. Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator
9.1. Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change
9.2. Company Facts and Ranking
9.3. Competitive Fall-Out Assessment
9.4. Abbott
9.5. Active Biotech
9.6. Advantagene
9.7. AEgera
9.8. AEterna Zentaris
9.9. Alchemia
9.10. Alethia Biotherapeutics
9.11. Allos Therapeutics
9.12. AlphaVax
9.13. Alseres Pharmaceuticals
9.14. Altor BioScience
9.15. Ambrilia Biopharma
9.16. American Gene Technology International
9.17. Amgen
9.18. Anavex Life Sciences
9.19. AndroBioSys
9.20. Antisense Pharma
9.21. Antisense Therapeutics
9.22. Antisoma
9.23. Aphios
9.24. ApopLogic Pharmaceuticals
9.25. Apotex
9.26. Aprea
9.27. Ardana
9.28. Ariad
9.29. ArQule
9.30. Array BioPharma
9.31. Ascenta Therapeutics
9.32. Ascepion Pharmaceuticals
9.33. Astellas
9.34. Astex Pharmaceuticals
9.35. AstraZeneca
9.36. Attenuon
9.37. AVI BioPharma
9.38. Bavarian Nordic
9.39. Baxter International
9.40. Bayer
9.41. Bellicum Pharmaceuticals
9.42. Bioenvision
9.43. Biogen Idec
9.44. BioLineRx
9.45. BioMarin
9.46. BioNetWorks
9.47. BioSante
9.48. Biostar
9.49. Boehringer Ingelheim
9.50. Bristol-Myers Squibb
9.51. BTG
9.52. Camurus
9.53. Cancer Research Technology
9.54. Cel-Sci
9.55. Celgene
9.56. Cell Therapeutics
9.57. Celldex Therapeutics
9.58. Celsion
9.59. Center of Molecular Immunology
9.60. Cephalon
9.61. Chemokine Therapeutics
9.62. Circadian Technologies
9.63. Cleveland BioLabs
9.64. Colby
9.65. Cosmo Bioscience
9.66. Curaxis
9.67. Curis
9.68. Cylene Pharmaceuticals
9.69. Cytokinetics
9.70. Daiichi Sankyo
9.71. Debiopharm
9.72. Dendreon
9.73. Dongkook Pharm
9.74. ECI
9.75. Eisai
9.76. Eli Lilly
9.77. Endo Pharmaceuticals
9.78. Endocyte
9.79. Ensemble Discovery
9.80. EntreMed
9.81. EpiCept
9.82. Esperance Pharmaceuticals
9.83. Etubics
9.84. EUSA Pharma
9.85. Exelixis
9.86. Ferring
9.87. Formula Pharmaceuticals
9.88. Galena Biopharma
9.89. Gemin X Pharmaceuticals
9.90. Generex
9.91. GENova Biotherapeutics
9.92. Genovax
9.93. Genta
9.94. Gerolymatos
9.95. Geron
9.96. Gilead Sciences
9.97. GlaxoSmithKline
9.98. GlycoGenesys
9.99. Got-a-Gene
9.100. GP Pharm
9.101. Green Cross
9.102. GTx
9.103. Harbor BioSciences
9.104. Hoffmann-La Roche
9.105. Human Genome Sciences
9.106. IGF Oncology
9.107. Immunocore
9.108. ImmunoGen
9.109. Immunomedics
9.110. ImmuPharma
9.111. Incyte Corporation
9.112. Infinity Pharmaceuticals
9.113. Inovio
9.114. Insmed
9.115. Insys Therapeutics
9.116. Introgen Therapeutics
9.117. Ipsen
9.118. Isis Pharmaceuticals
9.119. Ivy Medical Chemicals
9.120. Johnson & Johnson
9.121. Karo Bio
9.122. Kinex
9.123. Kyowa Hakko Kirin
9.124. Leo
9.125. Ligand
9.126. Lorus Therapeutics
9.127. Mannkind
9.128. Marillion Pharmaceuticals
9.129. Med Discovery
9.130. Meda
9.131. Medarex
9.132. MediGene
9.133. MedImmune
9.134. Mediolanum
9.135. Medivation
9.136. Menarini
9.137. Merck & Co
9.138. Merck KGaA
9.139. Merrion Pharmaceuticals
9.140. MethylGene
9.141. Mojave Therapeutics
9.142. Molecular Insight
9.143. Nektar Therapeutics
9.144. Nereus Pharmaceuticals
9.145. Nerviano Medical Sciences
9.146. Neurocrine Biosciences
9.147. Nippon Shinyaku
9.148. Non-industrial Sources
9.149. Northwest Biotherapeutics
9.150. Novacea
9.151. Novartis
9.152. Novogen
9.153. Oasmia
9.154. OncoGenex Pharmaceuticals
9.155. Oncothyreon
9.156. Oncovir
9.157. Orion Pharma
9.158. OSI Pharmaceuticals
9.159. Oxford BioMedica
9.160. Paladin Labs
9.161. Pantarhei Bioscience
9.162. Pepscan Therapeutics
9.163. Pfizer
9.164. Pharmacyclics
9.165. PharmaGap
9.166. PharmaMar
9.167. Philogen
9.168. Pierre Fabre
9.169. Progen
9.170. Progenics Pharmaceuticals
9.171. ProNAi Therapeutics
9.172. ProStrakan
9.173. Q Chip
9.174. QLT
9.175. Receptor BioLogix
9.176. Regeneron
9.177. Regulon
9.178. Rexahn
9.179. Salzburg Therapeutics
9.180. Samyang
9.181. Sanofi
9.182. Santaris Pharma
9.183. Sapphire Therapeutics
9.184. SBIO
9.185. SeleXel
9.186. Semafore Pharmaceuticals
9.187. Serometrix
9.188. SGX Pharmaceuticals
9.189. Shire
9.190. Siena Biotech
9.191. Soligenix
9.192. Sophiris Bio
9.193. SRI International
9.194. Supratek Pharma
9.195. Switch Pharma
9.196. Synta Pharmaceuticals
9.197. Taiho
9.198. Takeda
9.199. Tapestry Pharmaceuticals
9.200. Tau Therapeutics
9.201. Teva
9.202. Thallion Pharmaceuticals
9.203. Therion Biologics
9.204. Titan Pharmaceuticals
9.205. Tokai Pharmaceuticals
9.206. TopoTarget
9.207. Tracon Pharmaceuticals
9.208. Transgene
9.209. Twinstrand Therapeutics
9.210. Unigene
9.211. United Biomedical
9.212. Vaxon Biotech
9.213. Velacor Therapeutics
9.214. Vical
9.215. Vion Pharmaceuticals
9.216. VioQuest
9.217. Viralytics
9.218. ViroTarg
9.219. VM Discovery
9.220. Wilex
9.221. Xerion
9.222. Xoma
9.223. YM BioSciences
9.224. Zydus Cadila
10. Disclaimer
11. Drug Index
12. Company Index
List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of
Prostate Cancer Drugs
Figure 2: The Drug-Target Competitive Landscape of Prostate Cancer Drugs -
Larger Clusters
Figure 3: The Drug-Target Competitive Landscape Prostate Cancer Drugs -
Smaller Clusters
Figure 4: Head-to-Head Targeting Competitive Landscape of Prostate Cancer
Drugs - Larger Clusters
Figure 5: Head-to-Head Targeting Competitive Landscape of Prostate Cancer
Drugs - Smaller Clusters
Figure 6: Distribution of Compound Strategies among Prostate Cancer Drugs
Figure 7: Primary Sub-cellular Localization of Drug Targets
Figure 8: Number of Companies per Ranking Level
List of Tables
Table 1: Cancer Highlights'™ Five Pillar Drug Assessment
Table 2: Breakdown of the Included Prostate Cancer Drug Pipeline by Stage
of Development
Table 3: Head to Head Target Competition among Prostate Cancer Drugs
Table 4: Overview of Drug Target Strategy Themes
Table 5: Terminally Ceased Targets of Prostate Cancer Drugs
Table 6: Official Gene Symbol to Target Profle
Table 7: Mutation Frequencies of Prostate Cancer Drug Targets
Table 8: Identity of Drug Targets with Available Biological Structures
Table 9: Number of Target-Target Interactions among Targets of Prostate
Cancer Drugs
Table 10: Available Protein Expression Profiles of Prostate Cancer Drug
Targets
Table 11: Pathway Summary
Table 12: Drug Targets without any Identified Assigned Pathways
Table 13: Pathway Profiles According to BioCarta of Prostate Cancer Drug
Targets
Table 14: Pathway Profiles According to KEGG of Prostate Cancer Drug
Targets
Table 15: Pathway Profiles According to NetPath of Prostate Cancer Drug
Targets
Table 16: Number of Drug Target Strategies by their Highest Developmental
Stage and Uniqueness
Table 17: Top Competitive Target Strategies of Prostate Cancer Drugs
Table 18: New and Unique Target Strategies of Prostate Cancer Drugs in
Pre-registration or on the Marketed
Table 19: The Competition Through Close Mechanistic Approximation Between
Prostate Cancer Drugs Being Marketed
Table 20: New and Unique Target Strategies in Phase III Clinical
Development of Prostate Cancer Drugs
Table 21: The Competition Through Close Mechanistic Approximation Between
Phase III Prostate Cancer Drugs
Table 22: New and Unique Target Strategies in Phase II Clinical
Development of Prostate Cancer Drugs
Table 23: The Competition Through Close Mechanistic Approximation Between
Phase II Prostate Cancer Drugs
Table 24: New and Unique Target Strategies in Phase I Clinical Development
of Prostate Cancer Drugs
Table 25: The Competition Through Close Mechanistic Approximation Between
Phase I Prostate Cancer Drugs
Table 26: New and Unique Target Strategies in Preclinical Development of
Prostate Cancer Drugs
Table 27: The Competition Through Close Mechanistic Approximation Between
Preclinical Prostate Cancer Drugs
Table 28: Target Strategies of No Data, Suspended or Terminated Prostate
Cancer Drugs
Table 29: Connecting Target Strategy with Its Profile Identification Number
Table 30: The Competition Through Close Mechanistic Approximation Among
Prostate Cancer Drugs
Table 31: Overview of Compound Strategy Competition Among Prostate Cancer
Drugs
Table 32: Overview of the Competitive Landscape of Small Molecule Based
Prostate Cancer Drugs
Table 33: Competitive Comparison of Target Strategies of Small Molecule
Prostate Cancer Drugs
Table 34: Pursued Target Strategies of Small Molecule Drugs Based Prostate
Cancer Drugs
Table 35: Overview of the Competitive Landscape of Peptide Based Prostate
Cancer Drugs
Table 36: Competitive Comparison of Target Strategies of Peptide Based
Prostate Cancer Drugs
Table 37: Pursued Target Strategies of Peptide Based Prostate Cancer Drugs
Table 38: Overview of the Competitive Landscape of Protein Based Prostate
Cancer Drugs
Table 39: Competitive Comparison of Target Strategies of Protein Based
Prostate Cancer Drugs
Table 40: Pursued Target Strategies of Protein Based Prostate Cancer Drugs
Table 41: Overview of the Competitive Landscape of Antibody Based Prostate
Cancer Drugs
Table 42: Competitive Comparison of Target Strategies of Antibody Based
Prostate Cancer Drugs
Table 43: Pursued Target Strategies of Antibody Based Prostate Cancer Drugs
Table 44: Overview of the Competitive Landscape of Nucleic Acid Based
Prostate Cancer Drugs
Table 45: Competitive Comparison of Target Strategies of Nucleic Acid
Based Prostate Cancer Drugs
Table 46: Pursued Target Strategies of Nucleic Acid Based Prostate Cancer
Drugs
Table 47: Potential Forms of Cell Therapy
Table 48: Vectors in Gene Therapy
Table 49: Overview of the Competitive Landscape of Cell Therapy Based
Prostate Cancer Drugs
Table 50: Competitive Comparison of Target Strategies of Cell Therapy
Based Prostate Cancer Drugs
Table 51: Pursued Target Strategies of Cell Therapy Based Prostate Cancer
Drugs
Table 52: Overview of the Competitive Landscape of Gene Therapy Based
Prostate Cancer Drugs
Table 53: Competitive Comparison of Target Strategies of Gene Therapy
Based Prostate Cancer Drugs
Table 54: Pursued Target Strategies of Gene Therapy Based Prostate Cancer
Drugs
Table 55:Overview of the Competitive Landscape of Reformulated Prostate
Cancer Drugs
Table 56: Competitive Comparison of Target Strategies of Reformulated
Prostate Cancer Drugs
Table 57: Pursued Target Strategies of Reformulated Prostate Cancer Drugs
Table 58: Compound Strategies based on Sub-Cellular Localization of
Prostate Cancer Drug Targets
Table 59: Competitive Summary by Investigator of Prostate Cancer Drug
Development
Table 60: Summary Table of Corporate Changes in the Competitive Landscape
of Prostate Cancer Drug Development
Table 61: The Worst Ranking and the Highest Populated Level for Each of
the 15 Ranking Parameters
Table 62: Example of a Competitive Fall-Out Table (Targeting TOP2A)
Table 63: Abbott's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 64: Active Biotech's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 65: Advantagene's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 66: AEgera's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 67: AEterna Zentaris' Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 68: Alchemia's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 69: Alethia Biotherapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 70: Allos Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 71: AlphaVax's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 72: Alseres Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 73: Altor BioScience's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 74: Ambrilia Biopharma's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 75: American Gene Technology International's Included Prostate
Cancer Drugs and Competitive Fall-Out
Table 76: Amgen's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 77: Anavex Life Sciences' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 78: AndroBioSys' Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 79: Antisense Pharma's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 80: Antisense Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 81: Antisoma's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 82: Aphios' Included Prostate Cancer Drugs and Competitive Fall-Out
Table 83: ApopLogic Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 84: Apotex's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 85: Aprea's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 86: Ardana's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 87: Ariad's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 88: ArQule's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 89: Array BioPharma's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 90: Ascenta Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 91: Ascepion Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 92: Astellas' Included Prostate Cancer Drugs and Competitive Fall-Out
Table 93: Astex Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 94: AstraZeneca's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 95: Attenuon's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 96: AVI BioPharma's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 97: Bavarian Nordic's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 98: Baxter International's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 99: Bayer's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 100: Bellicum Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 101: Bioenvision's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 102: Biogen Idec's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 103: BioLineRx's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 104: BioMarin's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 105: BioNetWorks' Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 106: BioSante's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 107: Biostar's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 108: Boehringer Ingelheim's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 109: Bristol-Myers Squibb's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 110: BTG's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 111: Camurus' Included Prostate Cancer Drugs and Competitive Fall-Out
Table 112: Cancer Research Technology's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 113: Cel-Sci's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 114: Celgene's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 115: Cell Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 116: Celldex Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 117: Celsion's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 118: Center of Molecular Immunology's Included Prostate Cancer Drugs
and Competitive Fall-Out
Table 119: Cephalon's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 120: Chemokine Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 121: Circadian Technologies' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 122: Cleveland BioLabs' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 123: Colby's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 124: Cosmo Bioscience's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 125: Curaxis' Included Prostate Cancer Drugs and Competitive Fall-Out
Table 126: Curis' Included Prostate Cancer Drugs and Competitive Fall-Out
Table 127: Cylene Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 128: Cytokinetics' Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 129: Daiichi Sankyo's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 130: Debiopharm's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 131: Dendreon's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 132: Dongkook Pharm's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 133: ECI's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 134: Eisai's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 135: Eli Lilly's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 136: Endo Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 137: Endocyte's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 138: Ensemble Discovery's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 139: EntreMed's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 140: EpiCept's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 141: Esperance Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 142: Etubics' Included Prostate Cancer Drugs and Competitive Fall-Out
Table 143: EUSA Pharma's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 144: Exelixis' Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 145: Ferring's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 146: Formula Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 147: Galena Biopharma's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 148: Gemin X Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 149: Generex's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 150: GENova Biotherapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 151: Genovax's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 152: Genta's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 153: Gerolymatos' Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 154: Geron's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 155: Gilead Sciences' Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 156: GlaxoSmithKline's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 157: GlycoGenesys' Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 158: Got-a-Gene's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 159: GP Pharm's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 160: Green Cross' Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 161: GTx's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 162: Harbor BioSciences' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 163: Hoffmann-La Roche's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 164: Human Genome Sciences' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 165: IGF Oncology's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 166: Immunocore's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 167: ImmunoGen's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 168: Immunomedics' Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 169: ImmuPharma's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 170: Incyte Corporation's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 171: Infinity Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 172: Inovio's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 173: Insmed's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 174: Insys Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 175: Introgen Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 176: Ipsen's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 177: Isis Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 178: Ivy Medical Chemicals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 179: Johnson & Johnson's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 180: Karo Bio's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 181: Kinex's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 182: Kyowa Hakko Kirin's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 183: Leo's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 184: Ligand's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 185: Lorus Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 186: Mannkind's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 187: Marillion Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 188: Med Discovery's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 189: Meda's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 190: Medarex's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 191: MediGene's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 192: MedImmune's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 193: Mediolanum's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 194: Medivation's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 195: Menarini's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 196: Merck & Co's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 197: Merck KGaA's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 198: Merrion Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 199: MethylGene's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 200: Mojave Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 201: Molecular Insight's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 202: Nektar Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 203: Nereus Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 204: Nerviano Medical Sciences' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 205: Neurocrine Biosciences' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 206: Nippon Shinyaku's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 207: Non-industrial source's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 208: Northwest Biotherapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 209: Novacea's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 210: Novartis' Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 211: Novogen's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 212: Oasmia's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 213: OncoGenex Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 214: Oncothyreon's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 215: Oncovir's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 216: Orion Pharma's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 217: OSI Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 218: Oxford BioMedica's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 219: Paladin Labs' Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 220: Pantarhei Bioscience's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 221: Pepscan Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 222: Pfizer's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 223: Pharmacyclics' Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 224: PharmaGap's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 225: PharmaMar's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 226: Philogen's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 227: Pierre Fabre's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 228: Progen's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 229: Progenics Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 230: ProNAi Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 231: ProStrakan's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 232: Q Chip's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 233: QLT's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 234: Receptor BioLogix's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 235: Regeneron's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 236: Regulon's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 237: Rexahn's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 238: Salzburg Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 239: Samyang's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 240: Sanofi's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 241: Santaris Pharma's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 242: Sapphire Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 243: SBIO's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 244: SeleXel's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 245: Semafore Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 246: Serometrix's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 247: SGX Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 248: Shire's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 249: Siena Biotech's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 250: Soligenix's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 251: Sophiris Bio's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 252: SRI International's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 253: Supratek Pharma's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 254: Switch Pharma's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 255: Synta Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 256: Taiho's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 257: Takeda's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 258: Tapestry Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 259: Tau Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 260: Teva's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 261: Thallion Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 262: Therion Biologics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 263: Titan Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 264: Tokai Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 265: TopoTarget's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 266: Tracon Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 267: Transgene's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 268: Twinstrand Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 269: Unigene's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 270: United Biomedical's Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 271: Vaxon Biotech's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 272: Velacor Therapeutics' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 273: Vical's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 274: Vion Pharmaceuticals' Included Prostate Cancer Drugs and
Competitive Fall-Out
Table 275: VioQuest's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 276: Viralytics' Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 277: ViroTarg's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 278: VM Discovery's Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 279: Wilex's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 280: Xerion's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 281: Xoma's Included Prostate Cancer Drugs and Competitive Fall-Out
Table 282: YM BioSciences' Included Prostate Cancer Drugs and Competitive
Fall-Out
Table 283: Zydus Cadila's Included Prostate Cancer Drugs and Competitive
Fall-Out
This report includes 222 companies (Incl. Active, Out of Business and M&A)
plus their collaborators:
Abbott
Active Biotech
Advantagene
AEgera
AEterna Zentaris
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambrilia Biopharma
American Gene Technology International
Amgen
Anavex Life Sciences
AndroBioSys
Antisense Pharma
Antisense Therapeutics
Antisoma
Aphios
ApopLogic Pharmaceuticals
Apotex
Aprea
Ardana
Ariad
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVI BioPharma
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Bioenvision
Biogen Idec
BioLineRx
BioMarin
BioNetWorks
BioSante
Biostar
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Camurus
Cancer Research Technology
Celgene
Cell Therapeutics
Celldex Therapeutics
Cel-Sci
Celsion
Center of Molecular Immunology
Cephalon
Chemokine Therapeutics
Circadian Technologies
Cleveland BioLabs
Colby
Cosmo Bioscience
Curaxis
Curis
Cylene Pharmaceuticals
Cytokinetics
Daiichi Sankyo
Debiopharm
Dendreon
Dongkook Pharm
ECI
Eisai
Eli Lilly
Endo Pharmaceuticals
Endocyte
Ensemble Discovery
EntreMed
EpiCept
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Ferring
Formula Pharmaceuticals
Galena Biopharma
Gemin X Pharmaceuticals
Generex
GENova Biotherapeutics
Genovax
Genta
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
Got-a-Gene
GP Pharm
Green Cross
GTx
Harbor BioSciences
Hoffmann-La Roche
Human Genome Sciences
IGF Oncology
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
Inovio
Insmed
Insys Therapeutics
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Ivy Medical Chemicals
Johnson & Johnson
Karo Bio
Kinex
Kyowa Hakko Kirin
Leo
Ligand
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medivation
Menarini
Merck & Co
Merck KGaA
Merrion Pharmaceuticals
MethylGene
Mojave Therapeutics
Molecular Insight
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
Novartis
Novogen
Oasmia
OncoGenex Pharmaceuticals
Oncothyreon
Oncovir
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
Paladin Labs
Pantarhei Bioscience
Pepscan Therapeutics
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Philogen
Pierre Fabre
Progen
Progenics Pharmaceuticals
ProNAi Therapeutics
ProStrakan
Q Chip
QLT
Receptor BioLogix
Regeneron
Regulon
Rexahn
Salzburg Therapeutics
Samyang
Sanofi
Santaris Pharma
Sapphire Therapeutics
SBIO
SeleXel
Semafore Pharmaceuticals
Serometrix
SGX Pharmaceuticals
Shire
Siena Biotech
Soligenix
Sophiris Bio
SRI International
Supratek Pharma
Switch Pharma
Synta Pharmaceuticals
Taiho
Takeda
Tapestry Pharmaceuticals
Tau Therapeutics
Teva
Thallion Pharmaceuticals
Therion Biologics
Titan Pharmaceuticals
Tokai Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Transgene
Twinstrand Therapeutics
Unigene
United Biomedical
Vaxon Biotech
Velacor Therapeutics
Vical
Vion Pharmaceuticals
VioQuest
Viralytics
ViroTarg
VM Discovery
Wilex
Xerion
Xoma
YM BioSciences
Zydus Cadila
This report includes 394 prostate cancer drugs. From Ceased to Marketed.
Some examples are:
abarelix
abiraterone acetate
adecatumumab
aderbasib
AEZS-108
afatinib
aflibercept
ALT-801
alvocidib
amonafide dihydrochloride
amonafide malate
APC-100
APR-246
ARC-100
atrasentan
AVX-701
bafetinib
bevacizumab
BIBF-1120
bicalutamide
BMS-777607
BMS-936558
bortezomib
BP-GMAX-CD1
buserelin
Cabozantinib
carlumab
cediranib
celecoxib
cetuximab
cixutumumab
custirsen
danusertib
dasatinib
DCVax-prostate
degarelix
denosumab
deslorelin
DI-17E6
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dutasteride
E-75
entinostat
enzastaurin hydrochloride
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
figitumumab
flutamide
fulvestrant
gataparsen
GDC-0980
gefitinib
goserelin (1)
GTx-758
GVAX
GVX-3322
GX-301
HE-3235
histrelin
idronoxil
imatinib mesilate
inecalcitol
INSM-18
interleukins
intetumumab
ipilimumab
irosustat
ispinesib mesylate
KX2-391
lapatinib ditosylate
lestaurtinib
leucine-doxorubicin
leuprolide
leuprolide acetate
leuprorelin acetate
LIP-131I
LipoVIL12
litronesib
LOR-2040
LOR-2501
LY-2275796
MCS-110
MDV-3100
MLN-8237
Nab-docetaxel
nadroparin
nilutamide
nimotuzumab
oblimersen sodium
OGX-427
olaparib
olaratumab
orteronel
ozarelix
paclitaxel
paclitaxel polyglumex
panitumumab
panobinostat
perifosine
pertuzumab
plitidepsin
PLX-3397
ProstAtak
PROSTVAC
PRX-302
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
ramucirumab
retaspimycin
ridaforolimus
rilotumumab
romidepsin
ruxolitinib
sagopilone
sargramostim
SB-939
siltuximab
sipuleucel-T
sorafenib tosylate
TAK-448
tandutinib
tasquinimod
telomerase vaccine
temsirolimus
Tenarad
TOK-001
toremifene citrate
TRC-105
tremelimumab
trilostane
triptorelin
TroVax
TS-1
tucotuzumab celmoleukin
vandetanib
YM-155
zibotentan
Competitive Handbook towards Personalized Medicine in Prostate Cancer Additional Information published by BioSeeker Group AB in September 12, 2012. This report consists of 1493 Pages and the price starts from US $ 2925.
